Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 04/05/2024

2024 American Association for Cancer Research Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the AACR Annual Meeting External Link from April 5-10, 2024.

The following tables include presentations containing DCTD staff speakers and co-authors.

Oral Presentations

Date/Time Title/DCTD Speaker (If Applicable) ID
April 6
2:35-2:55 pm
Concepts in the design and analysis of COMBO MATCH External Link /James H. Doroshow MW08
April 7
3:35-3:50 pm
MTX-531, a first-in-class pan-PI3K inhibitor spares hyperinsulinemia yielding durable tumor regressions and resilience to adaptive resistance External Link 1230
April 8
1:30-2:30 pm
NCI Funding Opportunities and Grant Writing Strategies for New and Early-Stage Investigators External Link /Morgan O’Hayre; Sundar Venkatachalam; Christophe Marchand NIH06
April 9
2:30-3:30 pm
NCI’s Childhood Cancer Data Initiative: Building on the Power of Data and Community External Link /Gregory Reaman; Malcolm Smith; Ana Robles NIH10

Poster Presentations

Date/Time Title/DCTD Presenter (If Applicable) ID
April 7
1:30 PM - 5:00 PM
Multi-omic analysis of allelic expression patterns of imprinted and non-imprinted genes in cancer and their association with drug response External Link
Julia Krushkal
862/6
An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program External Link 1088/9
April 8
9:00 AM - 12:30 PM
A pro-oncogenic RAS-GTP:RAN-GAP complex facilitates nuclear protein export and has clinical implications External Link 2089/13
5-Aza-4'-thio-2'-deoxycytidine induces C to G transversions in a specific trinucleotide context and leads to acute lymphoid leukemia External Link 1484/22
The ROR1 antibody-drug conjugate, MK-2140, enhances the efficacy of established drugs in preclinical models of pediatric acute lymphoblastic leukemia External Link 1905/16
April 8
1:30 PM - 5:00 PM
Polymerase θ (POLθ) inhibitors (novobiocin, ART-558, RP6685) were tested with 22 approved and investigational agents in multi-cell type spheroids of genetically selected patient-derived human tumor cell lines External Link
Beverly Teicher
LB215 / 10
Development and performance of the National Cancer Institute’s HTS384 NCI60 screen: A modernized platform to support drug discovery and development by the worldwide cancer research community External Link 3090/1
Phase 1 trial of bortezomib and clofarabine combination in adults with refractory solid tumors External Link
Andre De Souza
CT120/28
Conservation of JAK-STAT signaling in canine lymphocytes responding to human IL-6, IL-7, and IL-1 alpha External Link 2837/24
April 9
9:00 AM - 12:30 PM
Combinations of Cdc-like kinase (CLK) inhibitors with targeted oncology agents or standard chemotherapy in patient-derived multi-cell type tumor spheroids External Link 4608/6
Evaluation of the prevalence and impact of molecular variation in the three-prime repair exonuclease 1 TREX1 across mammalian species and in human malignancies External Link
Mariam Konate
4345/15
April 9
1:30 PM - 5:00 PM
Atezolizumab clinical trial biopsies reveal varied immune landscapes in clear cell sarcoma and chondrosarcoma External Link CT263/22
Upregulation of TET2 expression by DNA methyltransferase (DNMT) inhibitors is associated with resistance in DNMT1 knockout colorectal cancer cells External Link
Sherry Yang
5881/25
Interleukin-1 upregulates dual oxidase 2 expression and ROS production in human pancreatic cancer cells External Link
David Mallick
5327/7
April 10
9:00 AM - 12:30 PM
Cholangiocarcinoma patient-derived models in the NCI Patient-Derived Models Repository External Link 6898/9
Expanding reported molecular characteristics for the NCI Patient-Derived Models Repository External Link 6911/2
Genomic landscape and stability of preclinical models in NCI's patient-derived models repository External Link 6914/25
Integrated proteogenomic analysis for the NCI patient-derived cancer model repository External Link 6915/26
In vivo efficacy of anti-B7-H3 antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd; DS-7300): An update from the Pediatric Preclinical In Vivo Testing (PIVOT) Program External Link LB402/3

Meet-the-Expert Presentations

Date/Time Topic Presenter
April 07
3:00 pm
Early-Stage Investigator Policy & R37 Extension Process Aniruddha Ganguly, Ph.D.
Cancer Diagnosis Program
April 07
4:30 pm
NCI Drug Development Resources: NExT, Stepping Stones, and Consultation Service Morgan O’Hayre, Ph.D.
Sharad Verma, Ph.D.
Developmental Therapeutics Program
April 08
11:00 am
Developmental Therapeutics Program Services and Repositories Christophe Marchand, Ph.D.
Developmental Therapeutics Program
April 08
1:30 pm
Program Project (P01) Grant Development Guidance Aniruddha Ganguly, Ph.D.
Cancer Diagnosis Program
April 09
11:30 am
Biospecimen Resources for the Research Community: Cooperative Human Tissue Network,
NCI National Clinical Trials Network and Specimen Resource Locator
Irina A. Lubensky, M.D.
Aniruddha Ganguly, Ph.D.
Cancer Diagnosis Program

Staff Kiosk Schedule – Exhibit Booth #1319

Date Time Presenter
April 07 1:00 - 3:00 pm Aniruddha Ganguly, Ph.D.
Cancer Diagnosis Program
3:00 - 5:00 pm Christophe Marchand, Ph.D.
Developmental Therapeutics Program
April 08 9:00 - 11:00 am Morgan O’Hayre, Ph.D.
Developmental Therapeutics Program
11:00 - 1:00 pm Yali Fu, Ph.D.
Developmental Therapeutics Program
1:00 - 3:00 pm Sharad Verma, Ph.D.
Developmental Therapeutics Program
3:00 - 5:00 pm Beverly Teicher, Ph.D.
Developmental Therapeutics Program
April 09 9:00 - 11:00 am Ana Robles, Ph.D.
Office of Cancer Clinical Proteomics Research
11:00 - 1:00 pm Aniruddha Ganguly, Ph.D.
Cancer Diagnosis Program
1:00 - 3:00 pm Sundar Venkatachalam, Ph.D.
Developmental Therapeutics Program
3:00 - 5:00 pm Christophe Marchand, Ph.D.
Developmental Therapeutics Program
April 10 9:00 - 12:30 pm Aniruddha Ganguly, Ph.D.
Cancer Diagnosis Program